title: [Use of subgrafting doses of peripheral stem cells is a new approach to overcoming hematological toxicity of multiple intensive courses of chemotherapy in children].
abstract: The authors examined 8 patients with pretreated relapsing or resistant solid tumors (Wilms'--4, rhabdomyosarcoma--3, synovial sarcoma--1) who received 16 courses of chemotherapy: iphosphamide, 1800 mg/m2/day (days 1-5), vepeside, 100 mg/m2/day (days 1-5), and carboplatin 500 mg/m2/day (day 1) (IVC) and 18 courses of therapy wherein iphosphamide was replaced by cyclophosphanum, 400 mg/m2/day (days 1-5) (CVC). The patients received 2-4 induction courses (n = 18) and 1-5 consolidation courses (n = 16) with reinfusion of peripheral stem cells (PSC). All PSC separations were performed after the first or second courses of IVC/CVE. There were no significant increases in the duration of leukopenia and thrombocytopenia, in the incidence of infection with a higher ordinal of a course performed by PSC maintenance. The findings suggest that the small doses of PSC stimulated by colony-stimulating factor can maintain hemopoiesis and decrease the rate of the estimated bone marrow depletion long after repeated courses of chemotherapy in patients with prognostically poor solid tumors.
authors.forename: M Ia
authors.initials: MIa
authors.lastname: Iankelevich
authors.forename: I S
authors.initials: IS
authors.lastname: Dolgopolov
authors.forename: L Iu
authors.initials: LIu
authors.lastname: Andreeva
authors.forename: R S
authors.initials: RS
authors.lastname: Ravshanova
authors.forename: D G
authors.initials: DG
authors.lastname: Izhogin
authors.forename: D M
authors.initials: DM
authors.lastname: Mkheidze
authors.forename: E V
authors.initials: EV
authors.lastname: Ogorodnikova
authors.forename: G L
authors.initials: GL
authors.lastname: Mentkevich
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D004342:Drug Hypersensitivity / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007680:Kidney Neoplasms / Q000628:therapy*; D008297:Male; D012189:Retrospective Studies; D012208:Rhabdomyosarcoma / Q000628:therapy; D013584:Sarcoma, Synovial / Q000628:therapy; D012983:Soft Tissue Neoplasms / Q000628:therapy*; D016896:Treatment Outcome; D009396:Wilms Tumor / Q000628:therapy